Canada markets open in 7 hours 41 minutes

Evofem Biosciences, Inc. (EVFM)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
Add to watchlist
0.0108-0.0010 (-8.47%)
At close: 03:32PM EDT
Full screen
Loading interactive chart...
  • PR Newswire

    Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

    Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.

  • PR Newswire

    Evofem Biosciences Announces Financial Results for the First Quarter of 2024

    The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include:

  • PR Newswire

    Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

    Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.